Comparison of 3D technologies and their applications to a cancer immunology model
Scientist in Biochemical and Cellular Pharmacology, Genentech, Inc.
Robert A. Blake (DPhil) is a scientist in drug and target discovery specializing in oncology drug development. He is currently a scientist in the department of Biochemical and Cellular Pharmacology at Genentech (previously at Sugen, Exelixis, and iPierian). He has published on the discovery of novel selective kinase inhibitors including the Src inhibitor SU6656, HSP90 inhibitor pharmacology and high content fluorescence imaging based methods. He was a member of the team that developed the angiogenesis inhibitor SUTENT (SU11248). His current focus is the development of drugs whose mechanism of action includes the degradation of the target protein and establishing more phenotypically relevant cellular assays for application to drug discovery.